Püriimidiini

Püriimidiini, also known as 6-mercaptopurine, is a medication used primarily in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). It belongs to a class of drugs known as purine analogs, which interfere with the production of DNA and RNA in rapidly dividing cells, thereby inhibiting the growth of cancer cells.

The mechanism of action of püriimidiini involves the inhibition of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which is crucial for the synthesis of nucleotides. By blocking this enzyme, püriimidiini prevents the production of essential building blocks for DNA and RNA, leading to the death of rapidly dividing cancer cells.

Püriimidiini is typically administered orally or intravenously. The dosage and duration of treatment depend on the type of cancer, the patient's overall health, and other medical factors. Common side effects include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, infection, and other complications.

It is important to note that püriimidiini is a potent immunosuppressive drug and should be used with caution in patients with weakened immune systems or those who are at risk for infections. Regular monitoring of blood counts and liver function is essential to manage these side effects and ensure the safety of the treatment.

Püriimidiini was first synthesized in the 1950s and has since been an important component in the treatment of various hematological malignancies. Its efficacy and safety profile have been well-documented in clinical studies, making it a valuable tool in oncology. However, like all medications, püriimidiini carries risks and should be used under the guidance of a healthcare professional.